Herantis Pharma Oyj
HRPMF
Other OTC3.51
USD
- -
- -
Herantis Pharma Oyj
HRPMF
(Other OTC)
Recent
price
3.51
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Herantis Pharma Oyj (HRTIS; HRPMF) is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders. The company offers HER-096, an advanced small-molecule synthetic chemical peptidomimetic derived from the active site of the cerebral dopamine neurotrophic factor (CDNF) protein, designed for subcutaneous administration to achieve blood-brain barrier penetration and neuroprotection; recombinant human CDNF (rhCDNF), a biological protein in Phase I development for Parkinson's disease; and exploratory candidates targeting related indications such as lymphedema via VEGF-C gene therapy. Herantis Pharma Oyj, founded in 2008 and headquartered in Espoo, Finland, operates primarily from Finland with a global development focus on unmet needs in neurology. In recent developments, the company reported topline data from its ongoing Phase 1b trial of HER-096 in Parkinson's patients during 2025, confirming safety and tolerability following positive Phase 1a results; secured EUR 3.6 million in research funding from The Michael J. Fox Foundation and Parkinson's UK to support the Phase 1b trial and biomarker studies; obtained a EUR 2.5 million grant from the European Innovation Council under a 2023 agreement; raised EUR 5.2 million through targeted share issuances in early 2025; and entered confidentiality agreements with 10 major pharmaceutical companies to explore partnerships ahead of Phase 2 funding.